



# Management of neonates at risk of early onset sepsis: a probability-based approach and recent literature appraisal

## Update of the Swiss national guideline of the Swiss Society of Neonatology and the Pediatric Infectious Disease Group Switzerland

Martin Stocker<sup>1</sup> · Flavia Rosa-Mangeret<sup>2</sup> · Philipp K. A. Agyeman<sup>3</sup> · Jane McDougall<sup>4</sup> · Christoph Berger<sup>5</sup> · Eric Giannoni<sup>6</sup>

Received: 11 August 2024 / Revised: 26 September 2024 / Accepted: 3 October 2024  
© The Author(s) 2024

### Abstract

In Switzerland and other high-income countries, one out of 3000 to 5000 term and late preterm neonates develops early onset sepsis (EOS) associated with a mortality of around 3%, while incidence and mortality of EOS in very preterm infants are substantially higher. Exposure to antibiotics for suspected EOS is disproportionally high compared to the incidence of EOS with consequences for future health and antimicrobial resistance (AMR). A safe reduction of unnecessary antibiotic treatment has to be a major goal of new management strategies and guidelines.

- Antibiotics should be administered immediately in situations with clinical signs of septic shock. *Group B streptococcus* (GBS) and *Escherichia coli* (*E. coli*) are the leading pathogens of EOS. Amoxicillin combined with an aminoglycoside remains the first choice for empirical treatment.
- Serial physical examinations are recommended for all neonates with risk factors for EOS. Neonates without any clinical signs suggestive of EOS should not be treated with antibiotics. In Switzerland, we do not recommend the use of the EOS calculator, a risk stratification tool, due to its unclear impact in a population with an observed antibiotic exposure below 3%.
- Not all neonates with respiratory distress should be empirically treated with antibiotics. Isolated tachypnea or respiratory distress starting immediately after delivery by elective caesarean section or a clearly assessed alternative explanation than EOS for clinical signs may point towards a low probability of sepsis. On the other hand, unexplained prematurity with risk factors has an inherent higher risk of EOS.
- Before the start of antibiotic therapy, blood cultures should be drawn with a minimum volume of 1 ml in a single aerobic blood culture bottle. This standard procedure allows antibiotics to be stopped after 24 to 36 h if no pathogen is detected in blood cultures. Current data do not support the use of PCR-based pathogen detection in blood as a standard method. Lumbar puncture is recommended in blood culture-proven EOS, critical illness, or in the presence of neurological symptoms such as seizures or altered consciousness.
- The accuracy of a single biomarker measurement to distinguish inflammation from infection is low in neonates. Therefore, biomarker guidance is not a standard part of decision-making regarding the start or stop of antibiotic therapy but may be used as part of an algorithm and after appropriate education of health care teams.
- Every newborn started on antibiotics should be assessed for organ dysfunction with prompt initiation of respiratory and hemodynamic support if needed. An elevated lactate may be a sign of poor perfusion and requires a comprehensive assessment of the clinical condition. Interventions to restore perfusion include fluid bolus with crystalloids and catecholamines. Neonates in critical condition should be cared for in a specialized unit.

---

Communicated by Daniele De Luca

Extended author information available on the last page of the article

- In situations with a low probability of EOS, antibiotics should be stopped as early as possible within the first 24 h after the start of therapy. In cases with microbiologically proven EOS, reassessment and streamlining of antibiotic therapy in neonates is an important step to minimize AMR.

*Conclusion:* This guideline, developed through a critical review of the literature, facilitates a probability-based approach to the management of neonates at risk of early onset sepsis.

---

**What is Known:**

- Neonatal exposure to antibiotics is disproportionately high compared with the incidence of early onset sepsis with implications for future health and antimicrobial resistance.

**What is New:**

- A probability-based approach may facilitate a more balanced management of neonatal sepsis and antibiotic stewardship.
- 

**Keywords** Neonatal sepsis · Early onset sepsis · Antimicrobial stewardship · Antibiotic therapy · Guideline

## Introduction

Most recommendations for neonates at risk for early onset sepsis (EOS) published more than 10 years ago were focused on early detection and prompt initiation of antibiotic therapy. These guidelines were mainly based on the assessment of clinical signs and risk factors. The approach was to start antibiotic therapy in every symptomatic neonate and in asymptomatic neonates with a high risk for EOS due to risk factors such as chorioamnionitis [1–6]. As clinical signs and risk factors for neonatal infection are non-specific, the vast majority of neonates started on antibiotic therapy do not have EOS. Therefore, a more balanced approach between effective sepsis management and antimicrobial stewardship (AMS) is needed. Nevertheless, an early detection of bacterial infection remains the cornerstone.

The purpose of this publication is to thoroughly evaluate and reassess the existing body of knowledge and to update the Swiss national guidelines published in 2013 [7]. We are using the word EOS to describe the continuum of bacterial and non-bacterial infection, infection with organ dysfunction (defined as sepsis in other age groups), and septic shock. Over the past 10 years, several countries have revised their guidelines, and these will be used as a basis and benchmark [1–6, 8]. The goal is to develop a management framework that can be implemented broadly. This document covers the assessment, early detection, and management of EOS. This includes diagnostic procedures, deciding when to start empirical antibiotic treatment, early interventions to prevent and treat organ dysfunction, and determining the appropriate duration of antibiotic therapy. The emphasis is not limited to term and late preterm infants but extends to newborns of all gestational ages. Over 90% of infants developing microbiologically proven EOS are symptomatic during the first 48 h. Therefore, we focus our management strategies on neonates within the first 2 days of life.

## Probability-based recommendations for the management of neonates at risk of EOS

Management guidelines for EOS have shown a significant evolution over time. In the past, there was a notable variability among different international guidelines, with many lacking a consensus on relevant topics [9]. However, recent years have seen a shift towards greater alignment, yet inconsistencies and ambiguities remain in some recommendations, such as the use of the EOS calculator or serial physical examinations [3, 6]. This evolution reflects the ongoing efforts to refine and improve the management strategies for EOS, adapting to new research findings and clinical practices.

Moreover, most guidelines have targeted specific groups, often categorized by gestational age, primarily addressing term and/or late preterm neonates [3–5]. The American Academy of Pediatrics (AAP) has further added to this landscape by issuing three different sets of guidelines: one for preterm infants below 35 gestational weeks, one for those above 35 weeks, and another for neonates born to GBS-positive mothers [1–3]. Additionally, the National Institute for Health and Care Excellence (NICE) has published an extensive guideline, spanning 60 pages, which, while comprehensive, adds to the complexity and presents challenges in terms of quick comprehension and application in clinical settings [6]. These examples highlight the ongoing struggle to balance detailed, specific guidance with the need for clarity and practicality in EOS management.

It is important to note that no management strategy can identify at birth all newborns who will develop EOS. It is not possible to avoid some amount of overtreatment due to the margin of safety needed not to miss a true sepsis case. With a probability-based approach, it may be possible to balance effective sepsis detection and care and AMR [10]. Therefore, the zero-risk approach treating all neonates with at least

some risk to develop EOS needs to be adapted by a balanced AMS culture. The aim is to early and effectively treat neonates with an ongoing bacterial infection early to achieve optimal short- and long-term outcomes but to expose fewer neonates to antibiotics.

In the process of developing new guidelines, it is essential to take into account local conditions, emphasize the importance of educational initiatives, and address the challenges associated with change management. Adopting a gradual approach, where changes are implemented in small, manageable steps, is often more practical and effective. Considering this, we kept important and established elements of the 2013 Swiss national guidelines while adapting it to decrease antibiotic use in low-risk situations [7].

## Critical appraisal of new evidence within the last decade

### Epidemiology

Several high-income countries have reported a decline in the incidence of EOS over the last 20 years [11–15]. The incidence of EOS is highest in extremely preterm infants (up to 13.5 per 1000 very preterm infants) and decreases with advancing gestational age [16–18]. In a retrospective study including more than 750,000 late preterm and term neonates in Europe, Australia, and North America, the incidence of EOS was 0.49 cases per 1000 live births with a range of 0.18 and 1.45 across networks [19]. The incidence of EOS in children born in Switzerland between 2012 and 2015 was 0.28 per 1000 live births in a prospective cohort study [18]. The severity of culture-proven EOS was considerable with septic shock in 26%, and a mortality of 18%, which is comparable with other studies [12, 20]. Yet, 43% of cases of EOS occurred in infants born at term and were associated with a low mortality rate of 3.2% [18]. Mortality rates in preterm infants with EOS are reported to be around ten times higher [12, 21, 22].

Conclusion: In Switzerland and other high-income countries, one out of 3000 to 5000 term and late preterm neonates develops EOS with a relatively low associated mortality of around 3%. Incidence and mortality of EOS in very preterm infants are substantially higher.

### Antimicrobial exposure and its effects in neonates

Exposure to antibiotics within the first week of life is disproportionately high compared to the incidence of EOS [19]. In a large network-based study in Europe, Australia, and North America, between 1.2 and 12.5% of late preterm and term neonates were started on antibiotic therapy leading

to an exposure of 135 (range 54–491) antibiotic days per 1000 live births [19]. In Switzerland, the rate of antibiotic exposure for late preterm and term neonates was between 2.5 and 3%. This overexposure to antibiotics at the beginning of life represents a high burden for the health of future generations [10, 23]. Antibiotic therapy perturbs the development of the individual microbiome with possible long-term consequences [10, 23–28]. An antibiotic course of 48 h within the first days of life leads to a significant change in the microbiome, still measurable at 1 year of age [29]. Moreover, several studies have described an association of antibiotic therapy in early life with chronic diseases as obesity, asthma, diabetes, juvenile arthritis, celiac, and inflammatory bowel disease later in life [29–31]. Whereas these studies are all retrospective with an inherent bias, some human and animal models give an insight regarding possible mechanisms involved in the interaction between microbiome and future diseases [24, 32, 33]. In preterm infants, studies showed an association of prolonged duration of antibiotic therapy with increased rates of necrotizing enterocolitis, bronchopulmonary dysplasia, late-onset sepsis, and death [34–36]. In addition, antibiotic therapy may lead to increased antimicrobial resistance (AMR) with the consequence that broad-spectrum antibiotics may be increasingly needed in neonatal care [29, 37–39]. Increased AMR is a major global health threat with more than 1.2 million deaths worldwide directly attributed to drug-resistant infections [40].

Conclusion: Exposure to antibiotics for suspected EOS is disproportionately high compared to the incidence of EOS with consequences for future health and AMR. A safe reduction of unnecessary antibiotic treatment is an important goal of new management strategies and guidelines.

### Risk factors

Following the implementation of universal screening policies for GBS and intrapartum antibiotic prophylaxis (IAP), maternal fever as the hallmark of chorioamnionitis has become the major risk factor for EOS [41]. However, the term chorioamnionitis has been used to label a heterogeneous group of conditions characterized by infection and/or inflammation with variable consequences for the newborn [42]. A consensus conference from the American College of Obstetricians and Gynecologists, the AAP, and the Society for Maternal–Fetal Medicine provided updated definitions that may distinguish isolated maternal fever from suspected and proven intrauterine infection or inflammation [42]. Instead of chorioamnionitis, the term “triple I” (intrauterine inflammation, infection, or both) was introduced to improve the categorization of such cases into (i) isolated maternal fever (not triple I), (ii) suspected, and (iii) confirmed triple I [43].

IAP for maternal GBS colonization is highly effective. In a cohort study of more than 7600 deliveries, IAP given at least 4 h before delivery was effective in 91% of cases to prevent GBS EOS, and when given less than 4 h before delivery still had some protective effect [44]. It is important to note that not all risk factors have the same “weight,” and a combination of risk factors may have more than an additive effect. Gestational age is the strongest single predictor of EOS. Therefore, preterm infants below 34 weeks of gestational age need to be assessed thoroughly including clinical information from obstetricians and midwives to explore important coexisting risk factors such as suspected or proven triple I.

Conclusion: Isolated maternal fever is not synonymous with chorioamnionitis. In contrast to the previous guidelines published in 2013, infants born to GBS-positive mothers exposed to adequate intrapartum antibiotic prophylaxis (IAP) are not considered to be at high risk of developing EOS.

### Pathogens of EOS and empirical treatment

GBS and *Escherichia coli* are the leading pathogens of EOS, where the proportion of EOS cases caused by *E. coli* compared to GBS is increasing, especially in preterm infants [12]. Additionally, viridans group streptococci, enterococci, *Staphylococcus aureus*, *Klebsiella* species and other Enterobacteriales, *Listeria monocytogenes*, and *Candida* spp. may cause EOS [12]. Empirical treatment should include amoxicillin in combination with an aminoglycoside, gentamicin, or amikacin. Due to good penetration of the blood–brain barrier, cephalosporins of the 3rd and 4th generation (cefotaxime, ceftazidime, or cefepime) should be considered in addition for suspected or proven meningitis with Gram-negative pathogens or septic shock [45]. In newborns with clinical signs suggestive of progression to septic shock, antibiotics should be started immediately after the collection of blood cultures [46]. In situations with ambiguous clinical signs, neonates need to be evaluated and observed, but antibiotics do not always need to be started immediately [46]. Besides bacterial EOS, non-bacterial EOS caused by fungal or viral infections has to be considered in specific situations. Congenital candidosis, a rare condition with known but non-specific risk factors such as prematurity, cerclage, rupture of membranes, and maternal vaginal candidosis, can present with skin lesions and progress to sepsis and septic shock requiring rapid initiation of systemic antifungals [47, 48]. EOS caused by Herpes simplex virus is rare but has to be considered in specific situations, and treatment with acyclovir has to be started early.

Conclusion: In situations with clinical signs of a septic shock, antibiotics should be administered immediately. GBS and *E. coli* are the leading pathogens of EOS. Amoxicillin

with an aminoglycoside is the first choice for empirical treatment.

### EOS calculator

The EOS calculator is a risk stratification tool with an integrated guideline regarding the start of antibiotics aiming to reduce unnecessary antibiotic use. Several studies were published within the last decade describing the implementation and use of the EOS calculator. The EOS calculator predicts the risk of developing EOS based on four risk factors (gestational age, highest maternal antepartum temperature, duration of rupture of membranes, maternal GBS colonization) and one protective factor (type and timing of maternal intrapartum antibiotics) and can be adjusted to the local incidence of EOS [49]. In addition, the EOS calculator also serves as a guideline and proposes a clinical recommendation to observe or to treat with antibiotics according to the estimated risk of sepsis adjusted to observed clinical signs. The threshold to recommend the start of antibiotic therapy was set at the probability to develop EOS in 3 out of 1000. The use of the sepsis calculator successfully reduced exposure to antibiotics from a range of 5 to 15% of all late preterm and term newborns to a range of 3 to 5% [49, 50]. The impact of this approach in settings with lower antibiotic treatment rates, such as shown in different networks in Europe including Switzerland, is unclear and may increase antibiotic exposure [19]. Importantly, the purpose of the sepsis calculator is not to identify all cases of EOS and information on the safety of this approach in different settings is still limited [11, 51, 52].

Conclusion: In Switzerland, we do not recommend the use of the EOS calculator due to the unclear impact of this tool in a population with an observed antibiotic exposure below 3%.

### Serial physical examinations

More than 90% of neonates developing EOS become symptomatic within the first 48 h of life, irrespective of IAP [53, 54]. The strategy to withhold antibiotics based on serial physical examinations in well-appearing neonates at risk for EOS has been recommended in past guidelines in Italy and Switzerland [7, 55]. The presence of risk factors helps to decide which neonates need to be closely observed (Table 1). Serial observations entail evaluating respiration, heart rate, temperature, peripheral perfusion, and skin color at least every 4 h. Implementation of serial physical examination to guide empiric treatment has reduced antibiotic exposure, without delaying antibiotic treatment of infected neonates [56–60]. The possibility to perform serial physical

**Table 1** Clinical signs and risk factors potentially related to neonatal early onset sepsis (EOS); definition of low probability of sepsis, serial, and continuous observation; start of antibiotics (compare Fig. 1)

Risk factors	<ul style="list-style-type: none"> <li>• Maternal group B streptococcus (GBS) colonization (vaginal/rectal swab: current or previous, bacteriuria) with intrapartum prophylaxis missing or inadequate and without elective caesarean section before the onset of labor and intraoperative rupture of membranes</li> <li>• Preterm birth</li> <li>• Prolonged rupture of membranes &gt; 18 h</li> <li>• Suspected triple I (maternal fever &gt; 38 °C plus any of the following symptoms: maternal WBC &gt; 15 G/l in the absence of corticosteroids, baseline fetal tachycardia, purulent fluid from the cervical os)</li> <li>• Confirmed triple I (suspected triple I plus any of the following: amniocentesis-proven infection, low glucose in amniotic fluid, placental pathology)</li> </ul>
Clinical signs	<ul style="list-style-type: none"> <li>• Tachypnea, respiratory distress, apnea</li> <li>• Tachycardia/bradycardia, poor peripheral perfusion, mottling</li> <li>• Temperature instability</li> <li>• Lethargy, irritability, muscular hypotonia, seizures</li> <li>• Vomiting, poor feeding</li> </ul>
Low probability of sepsis	<p>The following situations point towards a low probability of sepsis (assessment by specialist neonatologist/pediatrician):</p> <ul style="list-style-type: none"> <li>• Elective caesarean section (no rupture of membranes or contractions)</li> <li>• Isolated tachypnea</li> <li>• Respiratory distress starting immediately after delivery without risk factor</li> <li>• Other explanation for observed clinical signs</li> <li>• Rapid resolution of clinical signs within a few hours</li> </ul>
Serial observation	At the mother–child unit, monitor vital signs every 4 h for a total of 48 h: respiration, heart rate, temperature, peripheral perfusion, skin color
Continuous observation	At a specialized neonatology unit, monitoring continuously vital signs and clinical signs potentially related to infection, biomarker measurements according to local policy
Start of antibiotics	Blood culture of at least 1 ml needs to be taken before the start of antibiotics. Empirical treatment should include amoxicillin in combination with an aminoglycoside (gentamicin or amikacin). Prematurity due to chorioamnionitis or unexplained prematurity with the requirement for invasive ventilation and hemodynamic support with catecholamine are the main risk factors for death during EOS. In such scenarios, prompt initiation of antibiotics (within < 1 h) and support of vital functions are essential

examinations on the postnatal maternity wards without separating the infant from its mother is a big advantage of this approach but presents a challenge in case of standardized early discharge to home.

**Conclusion:** Neonates without any clinical signs suggestive of EOS should not be treated with antibiotics. In Switzerland, we recommend to keep the strategy of serial observations for asymptomatic infants with risk factors for EOS.

### Scenarios with a low probability of EOS

In the previous guideline, the recommendation was to treat all infants with clinical signs, regardless of an additional assessment of the probability of EOS. The justification for this approach was that clinical signs potentially associated with EOS are non-specific. In a retrospective cohort study after the implementation of an AMS initiative withholding antibiotic treatment in neonates with isolated respiratory distress without other risk factors in the USA, the rate of empirical treatment of newborns with respiratory distress was reduced from 95 to 41% without missing a true EOS case [61]. It is important to note that the design and

power of this study is insufficient to prove the safety of this approach. Nevertheless, the updated European guidelines on the management of respiratory distress syndrome highlight the importance of not treating all neonates with respiratory distress with antibiotics [62]. Cardiovascular signs such as impaired perfusion (mottled skin, prolonged capillary refill time, increased central-peripheral temperature difference), tachycardia, and hypotension have the highest diagnostic value among clinical signs for EOS [63, 64].

Whereas it is difficult to define a list of scenarios with a high risk of EOS, it may be possible to identify some situations with a low probability of EOS. Neonates delivered via elective caesarean section without prior rupture of membranes or contractions exhibit a low risk of sepsis. This is also true for neonates who present with isolated tachypnea or respiratory distress immediately following delivery, especially when an alternative cause for these symptoms is clearly identified (i.e., pneumothorax). Whereas respiratory distress in preterm infants is expected due to prematurity, situations with unexplained prematurity and additional risk factors such as triple I have an inherent higher risk of EOS. Unexplained prematurity or explained by triple I with a requirement of invasive ventilation and hemodynamic



support with catecholamines are the main risk factors for death during EOS [18].

**Conclusion:** Not all neonates with respiratory distress should be empirically treated with antibiotics. Neonates delivered via elective caesarean section, with an isolated tachypnea or respiratory distress starting immediately after delivery, or a clearly assessed alternative explanation than EOS for clinical signs may have a low probability of sepsis. On the other hand, unexplained prematurity and additional risk factors have an inherent higher risk of EOS.

## Blood and cerebrospinal fluid cultures

Detection of pathogens in blood cultures has improved due to automated blood culture systems and a better performance to detect low levels of bacteremia with a shorter time to positivity [65]. Blood cultures with a minimum of 1 ml blood sampled, primarily in an aerobic so-called pediatric bottle, before the start of antibiotic therapy have an excellent sensitivity [66–69]. Multifaceted interventions including education, guidelines, and feedback can increase compliance, optimize blood collection for culture, and improve sensitivity [70]. In a study of 594 bacteremic EOS episodes conducted in the USA, pathogens grew within 36 h of incubation in over 94% of episodes, regardless of maternal antibiotic administration [71]. These results were confirmed in other populations [72–74]. Therefore, the traditional 48-h period of empiric antibiotic treatment can be safely decreased to 24–36 h [75, 76].

To replace or increase the sensitivity and specificity of pathogen detection in blood, PCR-based methods to increase the yield of pathogen detection have been studied with mixed results [77–80]. Currently, PCR as a standard evaluation for suspected EOS cannot be recommended due to limited data on accuracy. On the other hand, secondary use of PCR in cases with a high suspicion of culture-negative EOS due to critical illness and negative blood cultures may help to evaluate and manage the situation [79, 81].

Lumbar puncture is recommended in blood culture-proven EOS, critical illness, or in the presence of neurological symptoms such as seizures or altered consciousness. It should be considered and thoroughly discussed in all cases of suspected EOS [82]. The accuracy of biomarker-guided decision-making regarding the need to perform a lumbar puncture is low [83, 84]. If the neonate's condition does not permit the safe performance of a lumbar puncture prior to starting antibiotics, the procedure can be deferred. In such cases, cell count and PCR to search for bacteria in the cerebrospinal fluid (CSF) can be performed when the neonate is stable to inform and guide further management [82].

**Conclusion:** Before the start of antibiotic therapy, blood cultures must be drawn with a minimum volume of 1 ml

in an aerobic blood culture bottle. This standard procedure allows antibiotics to be stopped after 24 to 36 h if no pathogen is detected in blood cultures and clinical circumstances allow. Lumbar puncture is recommended in blood culture-proven EOS, critical illness, or in the presence of neurological symptoms such as seizures or altered consciousness. Current data do not support the use of PCR-based methods in blood as a standard method to improve the accuracy of pathogen detection in suspected EOS cases.

## Biomarkers

Biomarkers have been used by clinicians for a long time with the aim to improve decision-making regarding the management of EOS. Only a small number of prospective studies with a sufficiently large sample size and biomarker implemented in an algorithm were published [85]. The most commonly used biomarkers are white blood count (WBC), C-reactive protein (CRP), interleukin 6 (IL-6), and procalcitonin (PCT) [86–90]. There is only one large randomized controlled trial using biomarker-guided decision-making to shorten the duration of empirically started antibiotic therapy in newborns [86]. Whereas analyses using machine learning underline the possible benefit of biomarkers, some published studies reported a risk for prolonged antibiotic therapy due to the implementation of biomarkers into decision-making for the management of EOS [56, 63, 91–93]. Recently, novel approaches like RNA signatures have been used in research settings, with the added benefit of combining several biomarkers for the categorization of patients [94, 95].

Overall, no biomarker has shown acceptable accuracy regarding the diagnosis of culture-proven EOS, and routine measurements of biomarkers as a standard procedure to diagnose EOS are not recommended [85]. Nevertheless, unexplained leukopenia (below 5 G/l) or elevated CRP, PCT, or IL-6, as well as signs of organ dysfunction such as elevated lactate, low platelets, or prolonged INR together with suspected infection, are associated with bacterial sepsis [96].

Serial negative PCT or CRP measurements may serve as an additional supporting argument for discontinuing antibiotic therapy in late preterm and term infants within 24 to 36 h. Normal values for PCT depend on age, and the most used target values for CRP are below 10 to 15 mg/l [85–87, 90]. The implementation of a biomarker-guided algorithm needs education and a change management of staff to prevent potential adverse consequences such as prolonged antibiotic therapy due to increased PCT or CRP values.

**Conclusion:** The accuracy of a single biomarker measurement to distinguish inflammation from infection is low. Therefore, biomarker guidance is not a standard part of decision-making regarding the start or stop of antibiotic therapy but may be used as part of an algorithm and after appropriate education of the local health care team.

## Organ dysfunction in sepsis

Since 2016, sepsis is defined, in adults, as a life-threatening organ dysfunction caused by a dysregulated host response to infection [97]. A consensus statement published in 2024 defined pediatric sepsis and septic shock accordingly [98]. Neonates are excluded in this new consensus statement, and an updated, international consensus definition for neonatal sepsis is still lacking [99, 100]. Newborns that die from bloodstream infection have a failure of respiratory and cardiovascular systems, which underlines the importance of including parameters of organ dysfunction in clinical assessment [18, 101]. A blood gas analysis with lactate is recommended in all neonates started on antibiotics to evaluate cardiovascular dysfunction in addition to clinical monitoring. If clinical signs of poor perfusion or an elevated lactate are observed, a fluid bolus of 10 ml/kg crystalloids should be administered immediately. If shock symptoms persist or lactate is not clearly decreasing, the start of a vasoactive agent, echocardiography, and care in a tertiary center are recommended [46]. In all cases, closely monitor respiratory rate, oxygen saturation, heart rate, temperature, blood pressure, and urine output. It is important to note that low blood pressure can be a late sign in septic shock in neonates. Chest X-ray may give important additional information for neonates in need of respiratory support. Blood coagulation studies are recommended in cases with septic shock, active bleeding, or low platelets. Investigations have to be repeated after specific therapy has been administered or if the organ dysfunction is worsening [46]. Organ dysfunction may be described and followed up using the neonatal Sequential Organ Failure Assessment (nSOFA) score which provides a reliable assessment for mortality in neonates with EOS [102].

**Conclusion:** Every newborn started on antibiotics should be assessed for organ dysfunction (respiratory, cardiovascular, and hematological dysfunction) with prompt initiation of respiratory and hemodynamic support if needed. An elevated lactate may be a sign of poor perfusion and requires a comprehensive assessment of the clinical condition. Interventions to restore perfusion include fluid boli with crystalloids and catecholamines. Care in a tertiary center is mandatory in case of critical illness.

## Reassessment of antibiotic therapy

If EOS is unlikely based on the course of clinical signs or there is an alternative explanation, clinicians should consider to stop antibiotic therapy at any time point to reduce unnecessary antibiotic exposure [10]. To be able to stop antibiotic therapy early in situations with a low probability of EOS, serial assessments of the neonate are mandatory.

An important role regarding the assessment of continuation of antibiotic therapy lies in the dynamic course of

clinical signs. It is unlikely that antibiotic therapy leads to the resolution of clinical signs due to invasive bacterial infection within a few hours and this fast resolution might point towards no infection, especially if an alternative explanation for the clinical presentation exists. Potential signs of infection within hours after delivery may be caused by a variety of diseases and conditions other than infection. On the other hand, the progression of clinical signs within the first 24 h after the start of antibiotics may point towards infection. Nevertheless, it is imperative to closely monitor and re-evaluate the patient for alternative explanations than sepsis.

After the detection of the causative pathogen, streamlining antibiotics is an important step to prevent the emergence of antimicrobial resistance (AMR). For questions regarding streamlining and duration of antibiotic therapy, consultation with infectious disease specialists should be considered in cases of culture-positive EOS.


Recent publications investigated the switch from parenteral to oral antibiotics for neonates in good general condition with negative cultures [103, 104]. In the RAIN study, an early switch from parenteral to oral amoxicillin with clavulanic acid in late preterm and term neonates with suspected EOS was not associated with an increased incidence of adverse outcomes [103]. Investigators in Denmark published similar results in a population-based, multicenter study with an overall low rate of 1.5% of term neonates started on antibiotics [104]. In the investigated population, exposure to antibiotics was not increased with the possibility to switch to oral therapy, but the duration of hospitalization was shortened. Nevertheless, the key question persists: Were these neonates truly infected, and would discontinuing antibiotic therapy have yielded the same outcomes as administering oral antibiotics?

**Conclusion:** In situations with a low probability of EOS, antibiotics should be stopped anytime as early as possible. In cases with microbiologically proven EOS, streamlining antibiotic therapy is an important step to optimize treatment and minimize AMR. In cases with a high suspicion for culture-negative sepsis, antibiotics should be discontinued latest after 5 days and not continued orally.

## Comprehensive guidelines for the management of EOS

Implementation of new guidelines has to be accompanied by an educational intervention including knowledge transfer as well as elements of change management. Whereas clarity and recommendations are high in some parts of the guideline, there remains room for local adaptation in other parts (for example, the use of biomarkers). Professionals in charge of

**Fig. 1** Algorithm to guide the management of newborns with clinical signs or risk factors potentially associated with early onset sepsis (EOS). Definitions and further information are provided in Table 1



neonatal care have to ensure implementation and compliance at their own institution. To evaluate the effect of the recommended guidelines, we have to measure future performance with at least a minimal dataset [10]. The minimal dataset used in the AENEAS study, describing the population, rate


of culture-positive EOS, and exposure to antibiotics within the first week of life, may serve as an example [19].

Figure 1 gives an overview of the algorithm regarding the observation of neonates at risk for EOS and the start of antibiotic therapy. Important definitions and further information

**Table 2** Definitions of contamination, culture-negative, and culture-positive neonatal early onset sepsis (EOS); information regarding the role of the dynamic aspect of clinical signs and biomarkers; and the need for lumbar puncture (compare Fig. 2)

Dynamic aspect of clinical signs	Progression of clinical signs points towards infection, whereas rapid resolution points towards no infection. Clinical deterioration within hours after delivery may be caused by a disease other than infection. If EOS is unlikely based on the course of clinical signs or there is an alternative explanation, consider to stop antibiotic therapy at any time point. To be able to stop antibiotic therapy early in situations with a low probability of EOS, serial assessments of the neonate are mandatory
Role of biomarkers	Serial negative PCT or CRP measurements may serve as an additional supporting argument for discontinuing antibiotic therapy in late preterm and term infants within 24 to 36 h. Increased biomarkers do not have a high positive predictive value for sepsis, and a diagnosis of culture-negative sepsis only due to increased biomarkers can lead to a substantial overuse of antibiotics
Lumbar puncture	We do not recommend performing a lumbar puncture on every neonate who is on antibiotic therapy. However, it should be considered and thoroughly discussed in all cases. Lumbar puncture is particularly recommended in cases with positive blood cultures, critical illness, or neurological symptoms such as seizures or altered consciousness. If the neonate's condition does not permit the safe performance of a lumbar puncture prior to starting antibiotics, the procedure can be deferred. In such cases, cell count and a PCR test for meningitis in the LCR can be performed when the neonate is stable to inform and guide further management
Contamination	Pathogens in positive blood cultures have to be assessed regarding the possibility of contamination. Skin pathogens combined with a low probability of EOS point towards contamination, and antibiotics may be stopped in these situations. In situations with central catheters inserted during resuscitation, catheter-related infection and removal of the line have to be considered
Culture-positive sepsis	Length of antibiotic therapy in microbiologically documented infections depends on the pathogen, site of infection, and the clinical course of the patient. As soon as the pathogen is known, antibiotic treatment has to be targeted. Invasive infections with Gram-negative pathogens need a longer duration of treatment (14 to 21 days) compared to Gram-positive sepsis (7 to 14 days). In any case of culture-positive EOS, consultation with infectious disease specialists should be considered
Culture-negative sepsis	If blood cultures remain negative after 24 to 36 h, antibiotic therapy should be stopped. A culture-negative sepsis may be considered in neonates with multiple clinical signs, critical illness, and negative blood cultures. The probability of a culture-negative sepsis depends on the correct sampling of blood cultures: Blood cultures with a minimum of 1 ml blood sampled before the start of antibiotic therapy have an excellent sensitivity. In cases with a high suspicion for culture-negative sepsis, antibiotics should be discontinued latest after 5 days and not continued orally





**Fig. 2** Algorithm to guide the duration of empirically started antibiotics. Definitions and further information are provided in Table 2

are given in Table 1. Figure 2 and Table 2 entail an overview regarding management after the start of empirical antibiotics for suspected EOS.

**Acknowledgements** Thanks to members of the Swiss society of Neonatology and the Paediatric Infectious Disease Group Switzerland reviewing the manuscript and agreeing the update of the guideline.

**Authors' contributions** All authors contributed to the guideline conception and design. Primary literature collection and analysis were performed by M.S. and E.G. The first draft of the manuscript was written by M.S. and E.G. and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

**Funding** Open access funding provided by University of Luzern.

**Data availability** No datasets were generated or analysed during the current study.

## Declarations

**Ethics approval** Not applicable.

**Consent to participate** Not applicable.

**Consent for publication** Not applicable.

**Competing interests** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in

the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

- Puopolo KM, Lynfield R, Cummings JJ et al (2019) Management of infants at risk for group B streptococcal disease. *Pediatrics* 144:e20191881. <https://doi.org/10.1542/peds.2019-1881>
- Puopolo KM, Benitz WE, Zaoutis TE et al (2018) Management of neonates born at  $\leq 34$  6/7 weeks' gestation with suspected or proven early-onset bacterial sepsis. *Pediatrics* 142:e20182896. <https://doi.org/10.1542/peds.2018-2896>
- Puopolo KM, Benitz WE, Zaoutis TE et al (2018) Management of neonates born at  $\geq 35$  0/7 weeks' gestation with suspected or proven early-onset bacterial sepsis. *Pediatrics* 142:e20182894. <https://doi.org/10.1542/peds.2018-2894>
- Romain O (2017) Antibiothérapie des infections néonatales bactériennes précoces chez les nouveau-nés nés à partir de 34 semaines d'aménorrhée. *Arch Pediatr Organe Off Soc Francaise Pediatr* 24(Suppl 3):S24–S28. [https://doi.org/10.1016/S0929-693X\(18\)30041-1](https://doi.org/10.1016/S0929-693X(18)30041-1)
- Jefferies AL (2017) Management of term infants at increased risk for early-onset bacterial sepsis. *Paediatr Child Health* 22:223–228. <https://doi.org/10.1093/pch/pxx023>
- (2021) Overview | Neonatal infection: antibiotics for prevention and treatment | Guidance | NICE. <https://www.nice.org.uk/guidance/ng195>. Accessed 10 Aug 2024
- Stocker M, Berger C, McDougall J et al (2013) Recommendations for term and late preterm infants at risk for perinatal bacterial infection. *Swiss Med Wkly* 143:w13873. <https://doi.org/10.4414/smw.2013.13873>
- Mahieu L, Langhendries J-P, Cossey V et al (2014) Management of the neonate at risk for early-onset group B streptococcal disease (GBS EOD): new paediatric guidelines in Belgium. *Acta Clin Belg* 69:313–319. <https://doi.org/10.1179/2295333714Y.0000000054>
- van Herk W, el Helou S, Janota J et al (2016) Variation in current management of term and late-preterm neonates at risk for early-onset sepsis: an international survey and review of guidelines. *Pediatr Infect Dis J* 35:494–500. <https://doi.org/10.1097/INF.0000000000001063>
- Stocker M, Klingenberg C, Navér L et al (2023) Less is more: antibiotics at the beginning of life. *Nat Commun* 14:2423. <https://doi.org/10.1038/s41467-023-38156-7>
- Benitz WE, Achten NB (2020) Finding a role for the neonatal early-onset sepsis risk calculator. *EClinicalMedicine* 19:100255. <https://doi.org/10.1016/j.eclinm.2019.100255>
- Stoll BJ, Puopolo KM, Hansen NI et al (2020) Early-onset neonatal sepsis 2015 to 2017, the rise of *Escherichia coli*, and the need for novel prevention strategies. *JAMA Pediatr* 174:e200593. <https://doi.org/10.1001/jamapediatrics.2020.0593>
- Schrag SJ, Farley MM, Petit S et al (2016) Epidemiology of invasive early-onset neonatal sepsis, 2005 to 2014. *Pediatrics* 138:e20162013. <https://doi.org/10.1542/peds.2016-2013>
- Cailes B, Kortsalioudaki C, Buttery J et al (2018) Epidemiology of UK neonatal infections: the neonIN infection surveillance network. *Arch Dis Child Fetal Neonatal Ed* 103:F547–F553. <https://doi.org/10.1136/archdischild-2017-313203>
- Fjalstad JW, Stensvold HJ, Bergseng H et al (2016) Early-onset sepsis and antibiotic exposure in term infants: a nationwide

- population-based study in Norway. *Pediatr Infect Dis J* 35:1–6. <https://doi.org/10.1097/INF.0000000000000906>
16. Flannery DD, Puopolo KM, Hansen NI et al (2022) Neonatal infections: insights from a multicenter longitudinal research collaborative. *Semin Perinatol* 46:151637. <https://doi.org/10.1016/j.semperi.2022.151637>
  17. Flannery DD, Edwards EM, Puopolo KM, Horbar JD (2021) Early-onset sepsis among very preterm infants. *Pediatrics* 148:e2021052456. <https://doi.org/10.1542/peds.2021-052456>
  18. Giannoni E, Agyeman PKA, Stocker M et al (2018) Neonatal sepsis of early onset, and hospital-acquired and community-acquired late onset: a prospective population-based cohort study. *J Pediatr* 201:106–114.e4. <https://doi.org/10.1016/j.jpeds.2018.05.048>
  19. Giannoni E, Dimopoulou V, Klingenberg C et al (2022) Analysis of antibiotic exposure and early-onset neonatal sepsis in Europe, North America, and Australia. *JAMA Netw Open* 5:e2243691. <https://doi.org/10.1001/jamanetworkopen.2022.43691>
  20. Saini SS, Shrivastav AK, Kumar J et al (2022) Predictors of mortality in neonatal shock: a retrospective cohort study. *Shock Augusta Ga* 57:199–204. <https://doi.org/10.1097/SHK.0000000000001887>
  21. Sgro M, Kobylanskii A, Yudin MH et al (2019) Population-based study of early-onset neonatal sepsis in Canada. *Paediatr Child Health* 24:e66–e73. <https://doi.org/10.1093/pch/pxy018>
  22. Vatne A, Klingenberg C, Rettedal S, Øymar K (2021) Early-onset sepsis in neonates - a population-based study in South-West Norway from 1996 to 2018. *Front Pediatr* 9:634798. <https://doi.org/10.3389/fped.2021.634798>
  23. Stiemsma LT, Michels KB (2018) The role of the microbiome in the developmental origins of health and disease. *Pediatrics* 141:. <https://doi.org/10.1542/peds.2017-2437>
  24. Brodin P (2022) Immune-microbe interactions early in life: a determinant of health and disease long term. *Science* 376:945–950. <https://doi.org/10.1126/science.abk2189>
  25. Uzan-Yulzari A, Turta O, Belogolovski A et al (2021) Neonatal antibiotic exposure impairs child growth during the first six years of life by perturbing intestinal microbial colonization. *Nat Commun* 12:443. <https://doi.org/10.1038/s41467-020-20495-4>
  26. Gasparrini AJ, Crofts TS, Gibson MK et al (2016) Antibiotic perturbation of the preterm infant gut microbiome and resistome. *Gut Microbes* 7:443–449. <https://doi.org/10.1080/19490976.2016.1218584>
  27. Bailey LC, Forrest CB, Zhang P et al (2014) Association of antibiotics in infancy with early childhood obesity. *JAMA Pediatr* 168:1063–1069. <https://doi.org/10.1001/jamapediatrics.2014.1539>
  28. Lu J, Claud EC (2019) Connection between gut microbiome and brain development in preterm infants. *Dev Psychobiol* 61:739–751. <https://doi.org/10.1002/dev.21806>
  29. Reyman M, van Houten MA, Watson RL et al (2022) Effects of early-life antibiotics on the developing infant gut microbiome and resistome: a randomized trial. *Nat Commun* 13:893. <https://doi.org/10.1038/s41467-022-28525-z>
  30. Dydensborg Sander S, Nybo Andersen A-M, Murray JA et al (2019) Association between antibiotics in the first year of life and celiac disease. *Gastroenterology* 156:2217–2229. <https://doi.org/10.1053/j.gastro.2019.02.039>
  31. Clarke SLN, Mageean KS, Maccora I et al (2022) Moving from nature to nurture: a systematic review and meta-analysis of environmental factors associated with juvenile idiopathic arthritis. *Rheumatol Oxf Engl* 61:514–530. <https://doi.org/10.1093/rheumatology/keab627>
  32. Cox LM, Yamanishi S, Sohn J et al (2014) Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. *Cell* 158:705–721. <https://doi.org/10.1016/j.cell.2014.05.052>
  33. Koren O, Konnikova L, Brodin P et al (2024) The maternal gut microbiome in pregnancy: implications for the developing immune system. *Nat Rev Gastroenterol Hepatol* 21:35–45. <https://doi.org/10.1038/s41575-023-00864-2>
  34. Dierikx TH, Deianova N, Groen J et al (2022) Association between duration of early empiric antibiotics and necrotizing enterocolitis and late-onset sepsis in preterm infants: a multicenter cohort study. *Eur J Pediatr* 181:3715–3724. <https://doi.org/10.1007/s00431-022-04579-5>
  35. Vatne A, Hapnes N, Stensvold HJ et al (2023) Early empirical antibiotics and adverse clinical outcomes in infants born very preterm: a population-based cohort. *J Pediatr* 253:107–114.e5. <https://doi.org/10.1016/j.jpeds.2022.09.029>
  36. Ting JY, Roberts A, Sherlock R et al (2019) Duration of initial empirical antibiotic therapy and outcomes in very low birth weight infants. *Pediatrics* 143:e20182286. <https://doi.org/10.1542/peds.2018-2286>
  37. Leo S, Curtis N, Zimmermann P (2022) The neonatal intestinal resistome and factors that influence it—a systematic review. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 28:1539–1546. <https://doi.org/10.1016/j.cmi.2022.07.014>
  38. Carvalho MJ, Sands K, Thomson K et al (2022) Antibiotic resistance genes in the gut microbiota of mothers and linked neonates with or without sepsis from low- and middle-income countries. *Nat Microbiol* 7:1337–1347. <https://doi.org/10.1038/s41564-022-01184-y>
  39. de Man P, Verhoeven BA, Verbrugh HA et al (2000) An antibiotic policy to prevent emergence of resistant bacilli. *Lancet Lond Engl* 355:973–978. [https://doi.org/10.1016/S0140-6736\(00\)90015-1](https://doi.org/10.1016/S0140-6736(00)90015-1)
  40. Antimicrobial Resistance Collaborators (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet Lond Engl* 399:629–655. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)
  41. Puopolo KM, Draper D, Wi S et al (2011) Estimating the probability of neonatal early-onset infection on the basis of maternal risk factors. *Pediatrics* 128:e1155–1163. <https://doi.org/10.1542/peds.2010-3464>
  42. Barth WH (2016) Lost in translation: the changing language of our specialty. *Obstet Gynecol* 127:423–425. <https://doi.org/10.1097/AOG.0000000000001326>
  43. Higgins RD, Saade G, Polin RA et al (2016) Evaluation and management of women and newborns with a maternal diagnosis of chorioamnionitis: summary of a workshop. *Obstet Gynecol* 127:426–436. <https://doi.org/10.1097/AOG.0000000000001246>
  44. Fairlie T, Zell ER, Schrag S (2013) Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal disease. *Obstet Gynecol* 121:570–577. <https://doi.org/10.1097/AOG.0b013e318280d4f6>
  45. Kim KS (2010) Acute bacterial meningitis in infants and children. *Lancet Infect Dis* 10:32–42. [https://doi.org/10.1016/S1473-3099\(09\)70306-8](https://doi.org/10.1016/S1473-3099(09)70306-8)
  46. Weiss SL, Peters MJ, Alhazzani W et al (2020) Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. *Intensive Care Med* 46:10–67. <https://doi.org/10.1007/s00134-019-05878-6>
  47. Darmstadt GL, Dinulos JG, Miller Z (2000) Congenital cutaneous candidiasis: clinical presentation, pathogenesis, and management guidelines. *Pediatrics* 105:438–444. <https://doi.org/10.1542/peds.105.2.438>


48. Kaufman DA, Coggins SA, Zanelli SA, Weitkamp J-H (2017) Congenital cutaneous candidiasis: prompt systemic treatment is associated with improved outcomes in neonates. *Clin Infect Dis Off Publ Infect Dis Soc Am* 64:1387–1395. <https://doi.org/10.1093/cid/cix119>
49. Escobar GJ, Puopolo KM, Wi S et al (2014) Stratification of risk of early-onset sepsis in newborns  $\geq$  34 weeks' gestation. *Pediatrics* 133:30–36. <https://doi.org/10.1542/peds.2013-1689>
50. Kuzniewicz MW, Puopolo KM, Fischer A et al (2017) A quantitative, risk-based approach to the management of neonatal early-onset sepsis. *JAMA Pediatr* 171:365–371. <https://doi.org/10.1001/jamapediatrics.2016.4678>
51. Achten NB, Plötz FB, Klingenberg C et al (2021) Stratification of culture-proven early-onset sepsis cases by the neonatal early-onset sepsis calculator: an individual patient data meta-analysis. *J Pediatr*. <https://doi.org/10.1016/j.jpeds.2021.01.065>
52. Snoek L, van Kassel MN, Krommenhoek JF et al (2022) Neonatal early-onset infections: comparing the sensitivity of the neonatal early-onset sepsis calculator to the Dutch and the updated NICE guidelines in an observational cohort of culture-positive cases. *EClinicalMedicine* 44:101270. <https://doi.org/10.1016/j.eclinm.2021.101270>
53. Bromberger P, Lawrence JM, Braun D et al (2000) The influence of intrapartum antibiotics on the clinical spectrum of early-onset group B streptococcal infection in term infants. *Pediatrics* 106:244–250. <https://doi.org/10.1542/peds.106.2.244>
54. Berardi A, Trevisani V, Di Caprio A et al (2023) Timing of symptoms of early-onset sepsis after intrapartum antibiotic prophylaxis: can it inform the neonatal management? *Pathog Basel Switz* 12:588. <https://doi.org/10.3390/pathogens12040588>
55. Berardi A, Tzialla C, Travan L et al (2018) Secondary prevention of early-onset sepsis: a less invasive Italian approach for managing neonates at risk. *Ital J Pediatr* 44:73. <https://doi.org/10.1186/s13052-018-0515-8>
56. Duvoisin G, Fischer C, Maucourt-Boulch D, Giannoni E (2014) Reduction in the use of diagnostic tests in infants with risk factors for early-onset neonatal sepsis does not delay antibiotic treatment. *Swiss Med Wkly* 144:w13981. <https://doi.org/10.4414/smw.2014.13981>
57. Berardi A, Buffagni AM, Rossi C et al (2016) Serial physical examinations, a simple and reliable tool for managing neonates at risk for early-onset sepsis. *World J Clin Pediatr* 5:358–364. <https://doi.org/10.5409/wjcp.v5.i4.358>
58. Berardi A, Spada C, Reggiani MLB et al (2019) Group B streptococcus early-onset disease and observation of well-appearing newborns. *PLoS ONE* 14:e0212784. <https://doi.org/10.1371/journal.pone.0212784>
59. Vatne A, Klingenberg C, Øymar K et al (2020) Reduced antibiotic exposure by serial physical examinations in term neonates at risk of early-onset sepsis. *Pediatr Infect Dis J* 39:438–443. <https://doi.org/10.1097/INF.0000000000002590>
60. Frymoyer A, Joshi NS, Allan JM et al (2020) Sustainability of a clinical examination-based approach for ascertainment of early-onset sepsis in late preterm and term neonates. *J Pediatr* 225:263–268. <https://doi.org/10.1016/j.jpeds.2020.05.055>
61. Capin I, Hinds A, Vomero B, et al (2020) Are early-onset sepsis evaluations and empiric antibiotics mandatory for all neonates admitted with respiratory distress? *Am J Perinatol*. <https://doi.org/10.1055/s-0040-1717070>
62. Sweet DG, Carnielli VP, Greisen G et al (2023) European consensus guidelines on the management of respiratory distress syndrome: 2022 update. *Neonatology* 120:3–23. <https://doi.org/10.1159/000528914>
63. Stocker M, Daunhawer I, van Herk W et al (2022) Machine learning used to compare the diagnostic accuracy of risk factors, clinical signs and biomarkers and to develop a new prediction model for neonatal early-onset sepsis. *Pediatr Infect Dis J* 41:248–254. <https://doi.org/10.1097/INF.00000000000003344>
64. Benitz WE, Wynn JL, Smith PB (2023) Neonatology questions and controversies: infectious disease, immunology, and pharmacology, 2nd ed. Elsevier, Philadelphia
65. Wilson ML (2020) Development of new methods for detecting bloodstream pathogens. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 26:319–324. <https://doi.org/10.1016/j.cmi.2019.08.002>
66. Hazen KC, Polage CR (2020) Using data to optimize blood bottle fill volumes and pathogen detection: making blood cultures great again. *Clin Infect Dis Off Publ Infect Dis Soc Am* 70:269–270. <https://doi.org/10.1093/cid/ciz203>
67. Woodford EC, Dhudasia MB, Puopolo KM et al (2021) Neonatal blood culture inoculant volume: feasibility and challenges. *Pediatr Res* 90:1086–1092. <https://doi.org/10.1038/s41390-021-01484-9>
68. Singh MP, Balegar VKK, Angiti RR (2020) The practice of blood volume submitted for culture in a neonatal intensive care unit. *Arch Dis Child Fetal Neonatal Ed* 105:600–604. <https://doi.org/10.1136/archdischild-2019-318080>
69. Gross I, Gordon O, Benenson S et al (1992) (2018) Using anaerobic blood cultures for infants younger than 90 days rarely showed anaerobic infections but increased yields of bacterial growth. *Acta Paediatr Oslo Nor* 107:1043–1048. <https://doi.org/10.1111/apa.14262>
70. Whelan S, Mulrooney C, Moriarty F et al (2024) Paediatric blood cultures - turning up the volumes: a before and after intervention study. *Eur J Pediatr* 183(7):3063–3071. <https://doi.org/10.1007/s00431-024-05544-0>
71. Kuzniewicz MW, Mukhopadhyay S, Li S et al (2020) Time to positivity of neonatal blood cultures for early-onset sepsis. *Pediatr Infect Dis J* 39:634–640. <https://doi.org/10.1097/INF.0000000000002632>
72. Dierig A, Berger C, Agyeman PKA et al (2018) Time-to-positivity of blood cultures in children with sepsis. *Front Pediatr* 6:222. <https://doi.org/10.3389/fped.2018.00222>
73. Huggard D, Powell J, Kirkham C et al (2021) Time to positivity (TTP) of neonatal blood cultures: a trend analysis over a decade from Ireland. *J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet* 34:780–786. <https://doi.org/10.1080/14767058.2019.1617687>
74. Marks L, de Waal K, Ferguson JK (2020) Time to positive blood culture in early onset neonatal sepsis: a retrospective clinical study and review of the literature. *J Paediatr Child Health* 56:1371–1375. <https://doi.org/10.1111/jpc.14934>
75. Sánchez PJ, Prusakov P, de Alba RC et al (2023) Short-course empiric antibiotic therapy for possible early-onset sepsis in the NICU. *J Perinatol Off J Calif Perinat Assoc* 43:741–745. <https://doi.org/10.1038/s41372-023-01634-3>
76. Kumar R, Setiady I, Bultmann CR et al (2023) Implementation of a 24-hour empiric antibiotic duration for negative early-onset sepsis evaluations to reduce early antibiotic exposure in premature infants. *Infect Control Hosp Epidemiol* 44:1308–1313. <https://doi.org/10.1017/ice.2022.246>
77. Oeser C, Pond M, Butcher P et al (2020) PCR for the detection of pathogens in neonatal early onset sepsis. *PLoS ONE* 15:e0226817. <https://doi.org/10.1371/journal.pone.0226817>
78. Obiero CW, Gumbi W, Mwakio S et al (2022) Detection of pathogens associated with early-onset neonatal sepsis in cord blood at birth using quantitative PCR. *Wellcome Open Res* 7:3. <https://doi.org/10.12688/wellcomeopenres.17386.3>



79. Stein A, Soukup D, Rath P-M, Felderhoff-Müser U (2023) Diagnostic accuracy of multiplex polymerase chain reaction in early onset neonatal sepsis. *Child Basel Switz* 10:1809. <https://doi.org/10.3390/children10111809>
80. Pammi M, Flores A, Versalovic J, Loeffel MM (2017) Molecular assays for the diagnosis of sepsis in neonates. *Cochrane Database Syst Rev* 2:CD011926. <https://doi.org/10.1002/14651858.CD011926.pub2>
81. Sinha M, Jupe J, Mack H et al (2018) Emerging technologies for molecular diagnosis of sepsis. *Clin Microbiol Rev* 31:e00089-e117. <https://doi.org/10.1128/CMR.00089-17>
82. Bedetti L, Miselli F, Minotti C et al (2023) Lumbar puncture and meningitis in infants with proven early- or late-onset sepsis: an Italian prospective multicenter observational study. *Microorganisms* 11:1546. <https://doi.org/10.3390/microorganisms11061546>
83. Sturgeon JP, Zanetti B, Lindo D (2018) C-reactive protein (CRP) levels in neonatal meningitis in England: an analysis of national variations in CRP cut-offs for lumbar puncture. *BMC Pediatr* 18:380. <https://doi.org/10.1186/s12887-018-1354-x>
84. Goldfinch CD, Korman T, Kotsanas D et al (2018) C-reactive protein and immature-to-total neutrophil ratio have no utility in guiding lumbar puncture in suspected neonatal sepsis. *J Paediatr Child Health* 54:848–854. <https://doi.org/10.1111/jpc.13890>
85. Stocker M, Giannoni E (2024) Game changer or gimmick: inflammatory markers to guide antibiotic treatment decisions in neonatal early-onset sepsis. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis* 30:22–27. <https://doi.org/10.1016/j.cmi.2023.02.021>
86. Stocker M, van Herk W, El Helou S et al (2017) Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPins). *Lancet Lond Engl* 390:871–881. [https://doi.org/10.1016/S0140-6736\(17\)31444-7](https://doi.org/10.1016/S0140-6736(17)31444-7)
87. Stocker M, van Herk W, El Helou S et al (2021) C-reactive protein, procalcitonin, and white blood count to rule out neonatal early-onset sepsis within 36 hours: a secondary analysis of the neonatal procalcitonin intervention study. *Clin Infect Dis Off Publ Infect Dis Soc Am* 73:e383–e390. <https://doi.org/10.1093/cid/ciaa876>
88. Küng E, Unterasinger L, Waldhör T et al (2023) Cut-off values of serum interleukin-6 for culture-confirmed sepsis in neonates. *Pediatr Res* 93:1969–1974. <https://doi.org/10.1038/s41390-022-02329-9>
89. Ebenebe CU, Hesse F, Blohm ME et al (2021) Diagnostic accuracy of interleukin-6 for early-onset sepsis in preterm neonates. *J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet* 34:253–258. <https://doi.org/10.1080/14767058.2019.1606194>
90. Hofer N, Zacharias E, Müller W, Resch B (2012) An update on the use of C-reactive protein in early-onset neonatal sepsis: current insights and new tasks. *Neonatology* 102:25–36. <https://doi.org/10.1159/000336629>
91. Mukherjee A, Davidson L, Anguava L et al (2015) NICE neonatal early onset sepsis guidance: greater consistency, but more investigations, and greater length of stay. *Arch Dis Child Fetal Neonatal Ed* 100:F248–249. <https://doi.org/10.1136/archdischild-2014-306349>
92. Singh N, Gray JE (2021) Antibiotic stewardship in NICU: Deimplementing routine CRP to reduce antibiotic usage in neonates at risk for early-onset sepsis. *J Perinatol Off J Calif Perinat Assoc* 41:2488–2494. <https://doi.org/10.1038/s41372-021-01110-w>
93. O'Sullivan C, Tsai DH-T, Wu IC-Y et al (2023) Machine learning applications on neonatal sepsis treatment: a scoping review. *BMC Infect Dis* 23:441. <https://doi.org/10.1186/s12879-023-08409-3>
94. Das A, Ariyakumar G, Gupta N et al (2024) Identifying immune signatures of sepsis to increase diagnostic accuracy in very preterm babies. *Nat Commun* 15:388. <https://doi.org/10.1038/s41467-023-44387-5>
95. Bai Y, Zhao N, Zhang Z et al (2023) Identification and validation of a novel four-gene diagnostic model for neonatal early-onset sepsis with bacterial infection. *Eur J Pediatr* 182:977–985. <https://doi.org/10.1007/s00431-022-04753-9>
96. Newman TB, Puopolo KM, Wi S et al (2010) Interpreting complete blood counts soon after birth in newborns at risk for sepsis. *Pediatrics* 126:903–909. <https://doi.org/10.1542/peds.2010-0935>
97. Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 315:801–810. <https://doi.org/10.1001/jama.2016.0287>
98. Schlapbach LJ, Watson RS, Sorce LR et al (2024) International consensus criteria for pediatric sepsis and septic shock. *JAMA* 331:665–674. <https://doi.org/10.1001/jama.2024.0179>
99. Wynn JL (2016) Defining neonatal sepsis. *Curr Opin Pediatr* 28:135–140. <https://doi.org/10.1097/MOP.0000000000000315>
100. Hayes R, Hartnett J, Semova G et al (2021) Neonatal sepsis definitions from randomised clinical trials. *Pediatr Res*. <https://doi.org/10.1038/s41390-021-01749-3>
101. Fleiss N, Coggins SA, Lewis AN et al (2021) Evaluation of the neonatal sequential organ failure assessment and mortality risk in preterm infants with late-onset infection. *JAMA Netw Open* 4:e2036518. <https://doi.org/10.1001/jamanetworkopen.2020.36518>
102. Yeo KT, Goh GL, Park WY et al (2023) Evaluation of the neonatal sequential organ failure assessment and mortality risk in neonates with early-onset infection. *Neonatology* 120:796–800. <https://doi.org/10.1159/000533467>
103. Keij FM, Kornelisse RF, Hartwig NG et al (2022) Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial. *Lancet Child Adolesc Health* 6:799–809. [https://doi.org/10.1016/S2352-4642\(22\)00245-0](https://doi.org/10.1016/S2352-4642(22)00245-0)
104. Malchau Carlsen EL, Dungu KHS, Lewis A et al (2023) Switch from intravenous-to-oral antibiotics in neonatal probable and proven early-onset infection: a prospective population-based real-life multicentre cohort study. *Arch Dis Child Fetal Neonatal Ed* 109:34–40. <https://doi.org/10.1136/archdischild-2023-325386>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Authors and Affiliations

Martin Stocker<sup>1</sup>  · Flavia Rosa-Mangeret<sup>2</sup> · Philipp K. A. Agyeman<sup>3</sup> · Jane McDougall<sup>4</sup> · Christoph Berger<sup>5</sup> · Eric Giannoni<sup>6</sup>

✉ Martin Stocker  
martin.stocker@luks.ch

<sup>1</sup> Clinic of Pediatric Intensive Care and Neonatology, Children's Hospital of Central Switzerland and University of Lucerne, Lucerne, Switzerland

<sup>2</sup> Neonatology and Paediatric Intensive Care Unit, Geneva University Hospitals and Geneva University, Geneva, Switzerland

<sup>3</sup> Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

<sup>4</sup> Department of Neonatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

<sup>5</sup> Department of Pediatrics, Children's University Hospital of Zurich and University of Zurich, Zurich, Switzerland

<sup>6</sup> Clinic of Neonatology, Department Mother-Woman-Child, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland